Are all aromatase inhibitors the same? A review of the current evidence

Breast

Volumn 13, Issue 1 SUPPL., 2004, Pages 10-18

  Jänicke, Fritz ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Hormonal therapy; Letrozole; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; MEGESTROL ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CATALYSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; THROMBOEMBOLISM; UTERUS CANCER;

EID: 10644250693     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2004.09.003     Document Type: Article

References (39)

1. Ferlay J Bray F Pisani P Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5. Lyon: IARCPress. 2001: Accessed 2004
2. A.J. Theobald Management of advanced breast cancer with endocrine therapy: The role of the primary healthcare team Int J Clin Pract 54 2000 665-669
3. S.M. Campos Aromatase inhibitors for breast cancer in postmenopausal women Oncologist 9 2004 126-136
4. H. Mouridsen M. Gershanovich Y. Sun et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 2001 2596-2606
5. H. Mouridsen M. Gershanovich Y. Sun et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2003 2101-2109
6. J. Bonneterre A. Buzdar J.M.A. Nabholtz et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomized trails designed for combined analysis. Arimidex Writing Committee; Investigators Committee Members. Cancer 92 2001 2247-2258
7. B. Fisher J.P. Costantino D.L. Wickerham et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371-1388
8. H. Mouridsen M. Gershanovich The role of aromatase inhibitors in the treatment of metastatic breast cancer Semin Oncol 30 2003 33-45
9. J. Geisler B. Haynes G. Anker M. Dowsett P.E. Lonning Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 20 2002 751-757
10. C. Rose O. Vtoraya A. Pluzanska et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: Comparison of the aromatase inhibitors letrozole and anastrozole Eur J Cancer 39 2003 2318-2327
11. W. Eiermann S. Paepke J. Appfelstaedt et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study Ann Oncol 12 2001 1527-1532
12. M.J. Ellis A. Coop B. Singh et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 2001 3808-3816
13. P.E. Goss S. Qi R.G. Josse et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats Bone 34 2004 384-392
14. P.E. Lonning J. Geisler L.E. Krag et al. Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk Proc Am Soc Clin Oncol (abstract) 23 2004 6
15. R. Paridaens P. Therasse L. Dirix et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - a randomized phase III trial of the EORTC Breast Group Proc Am Soc Clin Oncol (abstract) 23 2004 6
16. A.A. van Landeghem J. Poortman M. Nabuurs J.H. Thijssen Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue Cancer Res 45 1985 2900-2906
17. W.R. Miller P. Mullen P. Sourdaine C. Watson J.M. Dixon J. Telford Regulation of aromatase activity within the breast J Steroid Biochem Mol Biol 61 1997 193-202
18. A.U. Buzdar J.F.R. Robertson W. Eiermann J.M. Nabholtz An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane Cancer 95 2002 2006-2016
19. R.J. Santen T.J. Worgul E. Samojlik et al. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer N Engl J Med 305 1981 545-551
20. P. Lonning C. Pfister A. Martoni C. Zamagni Pharmacokinetics of third-generation aromatase inhibitors Semin Oncol 30 2003 23-32
21. A.S. Bhatnagar A.M. Brodie B.J. Long D.B. Evans W.R. Miller Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors J Steroid Biochem Mol Biol 76 2001 199-202
22. R.X. Song R.J. Santen R. Kumar et al. Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells Mol Cell Endocrinol 193 2002 29-42
23. S. Masamura S.J. Santner D.F. Heitjan R.J. Santen Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells J Clin Endocrinol Metab 80 1995 2918-2925
24. Smith I Dowsett M on behalf of the IMPACT Trialists Royal Marsden Hospital, London, United Kingdom. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Presented at: The 26th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas; December 3-6, 2003
25. L. Cataliotti A. Buzdar S. Noguchi J. Bines Efficacy of pre-operative Arimidex (anastrozole) compared with Tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer Eur J Cancer (abstract) 2 suppl 2004 69
26. M. Baum A. Buzdar J. Cuzick et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 2003 1802-1810
27. R.C. Coombes E. Hall L.J. Gibson et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081-1092
28. P.E. Goss J.N. Ingle S. Martino et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer N Engl J Med 349 2003 1793-1802
29. J.M. Nabholtz A. Buzdar M. Pollak et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncol 18 2000 3758-3767
30. J. Bonneterre B. Thürlimann J.F.R. Robertson et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. For the Arimidex Study Group J Clin Oncol 18 2000 3748-3757
31. A. Buzdar J. Douma N. Davidson et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate J Clin Oncol 19 2001 3357-3366
32. A.U. Buzdar W. Jonat A. Howell et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group Cancer 83 1998 1142-1152
33. M. Kaufmann E. Bajetta L.Y. Dirix et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group J Clin Oncol 18 2000 1399-1411
34. M. Gershanovich H.A. Chaudri D. Campos et al. Letrozole, a new oral aromatase inhibitor: Fandomised trial comparing 2.5 mg daiuly, 0.5 mg daily and aminoglutethimide in postmenopausal womem with advanced breast cancer. Letrozole International Trial Group (AR/BC3) Ann Oncol 9 1998 639-645
35. D.C. Allred J.M. Harvey M. Berardo G.M. Clark Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 1998 155-168
36. J.C. Newby S.R. Johnston I.E. Smith M. Dowsett Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer Clin Cancer Res 3 1997 1643-1651
37. P.E. Goss J.N. Ingle S. Martino et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer Proc Am Soc Clin Oncol 22 2004 88
38. P. Dombernowsky I. Smith G. Falkson et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J Clin Oncol 16 1998 453-461
39. A. Buzdar W. Jonat A. Howell et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. Arimidex Study Group J Clin Oncol 14 1996 2000-2011